Concepedia

Author

Calvin Cohen

Community Research Initiative

Also Known As

CALVIN J. COHEN, Calvin Cohen, Calvin J Cohen, Calvin J. Cohen, Calvin J. Cohen, Clifford L S Leen, Patty Coburn, Paul Cimoch, Trottier, Benoit

112

Publications

7.5K

Citations

37

H-Index

30

Concepts

All Affiliations

Community Research InitiativeGilead Sciences (United States)Harvard UniversityQuest Clinical Research (United States)University of North Carolina at Chapel Hill
CC

About

Calvin Cohen is an author at Community Research Initiative specializing in hiv, pharmacotherapy, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

11

14

2.3K

2

Public Health

3

3

194

3

Epidemiology

3

3

656

4

Health Policy

2

2

26

5

Health Sciences

1

1

11

Calvin Cohen

×

57

Publications

7.1K

Citations

35

H-Index

YearCitations

Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America

Jacob Lalezari, Keith Henry, Mary O’Hearn,

New England Journal of Medicine

2003

909

Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease

D. William Cameron, Margo Heath‐Chiozzi, Sven A. Danner,

The Lancet

1998

541

The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease

Kenneth A. Freedberg, Elena Losina, Milton C. Weinstein,

New England Journal of Medicine

2001

519

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

Bonaventura Clotet, Nicholas Bellos, Jean‐Michel Molina,

The Lancet

2007

480

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

Paul E. Sax, Edwin DeJesus, Anthony Mills,

The Lancet

2012

443

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

Calvin Cohen, Jaime Andrade‐Villanueva, Bonaventura Clotet,

The Lancet

2011

369

Antiviral Activity, Pharmacokinetics, and Dose Response of the HIV-1 Integrase Inhibitor GS-9137 (JTK-303) in Treatment-Naive and Treatment-Experienced Patients

Edwin DeJesus, Daniel Berger, Martin Markowitz,

JAIDS Journal of Acquired Immune Deficiency Syndromes

2006

268

Use of Genotypic Resistance Testing To Guide HIV Therapy: Clinical Impact and Cost-Effectiveness

Milton C. Weinstein, Sue J. Goldie, Elena Losina,

Annals of Internal Medicine

2001

240

Ritonavir and saquinavir combination therapy for the treatment of HIV infection

D. William Cameron, Anthony J. Japour, Yi Xu,

AIDS

1999

198

A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy

Calvin Cohen, Susan C. Hunt, Michael Sension,

AIDS

2002

197

Page 1